Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion

American Journal of Gastroenterology

Volumn 98, Issue 2, 2003, Pages 301-307

  Metz, David C ^a   Soffer, Elaine ^b   Forsmark, Chris E ^b   Cryer, Byron ^b   Chey, William ^b   Bochenek, Wieslaw ^b   Pisegna, Joseph R ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MAGALDRATE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BACKACHE; CLINICAL ARTICLE; CONSTIPATION; DEATH; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; LONG TERM CARE; MALE; NAUSEA; NEUROPATHY; OPTIC NERVE DISEASE; PRIORITY JOURNAL; SIDE EFFECT; STOMACH ACID SECRETION; VISUAL IMPAIRMENT; ZOLLINGER ELLISON SYNDROME;

EID: 0037285703     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07262.x     Document Type: Article

References (26)

1. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955;142:709-23.
2. Metz DC, Jensen RT. Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome. In: Mignon M, Jensen RT, eds. Endocrine tumors of the pancreas. Frontiers in gastrointestinal research, vol 23. Basel, Karger: 1995:240-57.
3. Collen MJ, Sheridan MJ. Definition for idiopathic gastric acid hypersecretion. Dig Dis Sci 1991;36:1371-6.
4. Jensen RT. Basis for failure of cimetidine in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1984;29:363-6.
5. Metz DC, Pisegna JR, Fishbeyn VA, et al. Current maintenance doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992;103:1498-1508.
6. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661-9.
7. Fellenius E, Berglindh T, Sachs G, et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+/K+) ATPase. Nature 1981;290:159-61.
8. Sachs G, Modlin IM. The regulation of gastric acid secretion. In: Sachs G, Modlin IM, eds. Acid related disease: Biology and treatment. Konstanz, Germany: Schnetztor-Verlag, 1998:37-112.
9. Sachs G, Modlin IM. Pharmacology of acid secretion. In: Sachs G, Modlin IM, eds. Acid related disease: Biology and treatment. Konstanz, Germany: Schnetztor-Verlag, 1998:113-46.
10. Jensen RT, Metz DC, Koviack PD, Feigenbaum KM. Prospective study of the long-term efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1993;7(suppl 1):41-50.
11. Metz DC, Strader DB, Orbuch M, et al. Use of omeprazole in Zollinger-Ellison syndrome: A prospective nine-year study on efficacy and safety. Aliment Pharmacol Ther 1993;7:597-610.
12. Hirschowitz BI, Simmons J, Mohnen J. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: A prospective 10-year study. Aliment Pharmacol Ther 2001;15:1795-806.
13. Carswell CI, Goa KL. Rabeprazole: An update of its use in acid-related disorders. Drugs 2001;61:2327-56.
14. Desir B, Poitras P. Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome. Can J Gastroenterol 2001;15:795-8.
15. Lew EA, Pisegna JR, Starr JA, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 2000;118:696-704.
16. Metz DC, Forsmark C, Lew EA, et al. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Am J Gastroenterol 2001;96:3274-80.
17. Vinayek R, Frucht H, London F, et al. Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. Gastroenterology 1990;99:10-6.
18. Otani Y, Kitajima M, Sugiyama M, et al. Inhibitory effects of intravenous lansoprazole on gastric acid hypersecretion in patients with postoperative stress. J Clin Gastroenterol 1995;20(suppl 2):S22-6.
19. Gibril F, Venzon DJ, Ojeaburu JV, et al. Prospective study of the natural history of gastrinoma in patients with MEN1: Definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 2001;86:5282-93.
20. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999;17:615-30.
21. Maton PN, Frucht H, Vinayek R, et al. Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: A prospective study. Gastroenterology 1988;94:294-9.
22. Frucht H, Maton PN, Jensen RT. Use of omeprazole in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1991;36: 394-404.
23. Lloyd-Davies KA, Rutgersson K, Solvell L. Omeprazole in the treatment of Zollinger-Ellison syndrome: A 4-year international study. Aliment Pharmacol Ther 1988;2:13-32.
24. Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992;103:1498-508.
25. Lessell S. Omeprazole and ocular damage. Concerns on safety of drug are unwarranted. Br Med J 1998;316:67.
26. Sachs G. Omeprazole and ocular damage. Lack of causality holds true. Br Med J 1998;316:67-8.